Renin-angiotensin inhibitors reprogram the tumour immune microenvironment by Dr. Dora Lucia Vallejo-Ardila (1).mp4 (12.93 MB)

Renin-angiotensin inhibitors reprogram tumor immune microenvironment

Download (12.93 MB)
media
posted on 24.09.2020 by Dora Lucia Ardila
Colorectal cancer (CRC) is the third most common cancer diagnosis, and it is ranked second as cancer causing death for both sexes combined in the developed world. Over half of the patients with CRC will develop metastatic liver disease. Subsequently colorectal liver metastases (CRLM) results in death in at least two thirds of these patients. Surgical resection of CRLM is the only potential curative treatment and combined with chemotherapy can achieve 5-year survival rates of 40 to 60%. However, the majority of these patients will develop tumor recurrence, most commonly in the liver. Current research to improve this clinical outcome is focusing on identifying strategies to immunomodulate tumor microenvironment. Renin-angiotensin inhibitors (RASi) have shown anti-tumor effects that may have a profound impact in cancer therapy.

Funding

DL Vallejo-Ardila is supported by the Department of Science, Technology, and Innovation (COLCIENCIAS-Colombia) (Ph. D overseas 679 program) and the University of Melbourne, Faculty of Medicine, Dentistry and Health Sciences (Postgraduate Research Scholarship 2018-2021).

History

Licence

Exports